US45256X1037
US45256X1037
ImmunityBio, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 11.14B EUR | 9.22B EUR | 8.03B EUR | 2B EUR |
Enterprise Value | 11.37B EUR | 9.96B EUR | 8.55B EUR | 2.43B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -75.07x | -- | -- | -- |
Price to Sales | 67.19x | 55.62x | 56.98x | 20.7x |
Price to Book | -- | -- | -- | -- |
EV/Revenue | 68.61x | 60.07x | 60.63x | 25.14x |
EV/EBITDA | -48.34x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.67% | -3.13% | -3.73% | -11.09% |